1st Patient Dosed in Trial of IO102-Keytruda Combo in Treating Metastatic Lung Cancer
News
IO Biotech has dosed the first patient in a clinical trial testing the safety and efficacy of IO102 in combination with Merck’s Keytruda (pembrolizumab) as a first-line treatment for patients with metastatic non-small ... Read more